Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
PharmAthene Inc. said Tuesday its experimental anthrax vaccine SparVax met an important goal in clinical testing, as a study showed the vaccine is stable when stored for up to three years.
The company said the 36-month stability result is an important milestone in its research contract with the U.S. government, and it said similar vaccines have had problems demonstrating stability.
PharmAthene said SparVax is a recombinant vaccine that is made through a simpler, more efficient process than the only currently approved anthrax vaccine, Emergent BioSolutions Inc.'s BioThrax. The company says it would be able to make 150 million doses of SparVax in a year, if necessary. PharmAthene is developing the vaccine with funding from the National Institute of Allergy and Infectious Disease, National Institutes of Health, and the Biomedical Advanced Research and Development Authority, a unit of the Department of Health and Human Services.
Shares of PharmAthene rose 9 cents, or 2.9 percent, to $3.04 in afternoon trading.